Gerald Webersinke
YOU?
Author Swipe
View article: NALIRIFOX in the treatment of metastatic pancreatic ductal adenocarcinoma: an exploratory analysis of real-world data
NALIRIFOX in the treatment of metastatic pancreatic ductal adenocarcinoma: an exploratory analysis of real-world data Open
View article: Biochemical phenotype of hypophosphatasia in asymptomatic individuals carrying <i>ALPL</i> variants
Biochemical phenotype of hypophosphatasia in asymptomatic individuals carrying <i>ALPL</i> variants Open
Hypophosphatasia (HPP) is the rare metabolic disorder caused by variants in the ALPL gene, resulting in deficient activity of tissue-nonspecific alkaline phosphatase (ALP). This leads to accumulation of substrates contributing to impaired …
View article: The ALPL gene variant project: results of the first 100 reclassified variants
The ALPL gene variant project: results of the first 100 reclassified variants Open
Hypophosphatasia (HPP) is an inherited disorder that affects bone and tooth mineralization, among other body systems. HPP is caused by pathogenic variants in the alkaline phosphatase-liver (ALPL) gene, which encodes tissue nonspecific alka…
View article: Circulating Tumor DNA (ctDNA) Dynamics Predict Early Response to Treatment in Metastasized Gastroesophageal Cancer (mGEC) After 2 Weeks of Systemic Treatment
Circulating Tumor DNA (ctDNA) Dynamics Predict Early Response to Treatment in Metastasized Gastroesophageal Cancer (mGEC) After 2 Weeks of Systemic Treatment Open
mGEC is associated with poor overall survival (OS) of approximately 4–10 months. CtDNA is emerging as a promising prognostic biomarker with high potential for early relapse detection. However, until now, there was little knowledge on seria…
View article: Exceptional sustained long-term complete response to Tepotinib in a <i>MET</i>-amplified advanced intrahepatic biliary tract cancer failing Durvalumab plus Cisplatin and Gemcitabine
Exceptional sustained long-term complete response to Tepotinib in a <i>MET</i>-amplified advanced intrahepatic biliary tract cancer failing Durvalumab plus Cisplatin and Gemcitabine Open
Background Biliary tract cancers (BTCs) are a diverse group of malignancies with varied genetic backgrounds. The prevalence of intrahepatic cholangiocarcinoma (iCC) is increasing, particularly in Western countries. Despite advancements in …
View article: Exploring the impact of durvalumab on biliary tract cancer: insights from real-world clinical data
Exploring the impact of durvalumab on biliary tract cancer: insights from real-world clinical data Open
This study confirms the phase 3 trial results of durvalumab with platinum and gemcitabine, providing a substantial real-world dataset with detailed molecular characterization. No specific patient subgroup showed a markedly better response …
View article: Improved Outcomes in Myelofibrosis after Allogeneic Stem-Cell Transplantation in the Era of Ruxolitinib Pretreatment and Intensified Conditioning Regimen—Single-Center Analysis
Improved Outcomes in Myelofibrosis after Allogeneic Stem-Cell Transplantation in the Era of Ruxolitinib Pretreatment and Intensified Conditioning Regimen—Single-Center Analysis Open
(1) Background: Allogeneic hematopoietic stem-cell transplantation (allo-HSCT) is the only treatment with the potential for cure in patients with myelofibrosis (MF). However, the risk of graft rejection, which is particularly high in MF, a…
View article: Exploring the impact of Durvalumab on biliary tract cancer- insights from real world clinical data
Exploring the impact of Durvalumab on biliary tract cancer- insights from real world clinical data Open
Introduction This study assesses the effectiveness of durvalumab with platinum and gemcitabine for biliary tract cancers (BTC). It aims to confirm the Topaz-1 trial results in a real-world context and explore the link between BTC molecular…
View article: Understanding homologous recombination repair deficiency in biliary tract cancers: clinical implications and correlation with platinum sensitivity
Understanding homologous recombination repair deficiency in biliary tract cancers: clinical implications and correlation with platinum sensitivity Open
Patients with HRRm with BTC showed a potential advantage in OS following platinum-based first-line chemotherapy, presumably attributed to enhanced opportunities for targetable coalterations. Further investigation is needed to outline HRR w…
View article: IMPI: An Interface for Low-Frequency Point Mutation Identification Exemplified on Resistance Mutations in Chronic Myeloid Leukemia
IMPI: An Interface for Low-Frequency Point Mutation Identification Exemplified on Resistance Mutations in Chronic Myeloid Leukemia Open
Background: In genomics, highly sensitive point mutation detection is particularly relevant for cancer diagnosis and early relapse detection. Next-generation sequencing combined with unique molecular identifiers (UMIs) is known to improve …
View article: 88P Circulating tumor DNA (ctDNA) as precision medicine marker for neoadjuvant chemotherapy vs upfront surgery in primary resectable localized pancreatic cancer
88P Circulating tumor DNA (ctDNA) as precision medicine marker for neoadjuvant chemotherapy vs upfront surgery in primary resectable localized pancreatic cancer Open
Circulating tumor DNA (ctDNA) has emerged as a promising biomarker displaying systemic tumor burden in presumed localized pancreatic cancer (lPC). However, clinical applicability for neoadjuvant chemotherapy (NACT) guidance was flawed by l…
View article: 89P ctDNA as an unifiable biomarker to predict response to treatment after 2 weeks of chemotherapy at the same cut-off for metastatic GEC, PC and CRC
89P ctDNA as an unifiable biomarker to predict response to treatment after 2 weeks of chemotherapy at the same cut-off for metastatic GEC, PC and CRC Open
ctDNA has emerged as a promising biomarker in gastrointestinal cancer. However, definitions for detectability and cut-offs are reported very heterogeneously. We evaluated for the first time in humans responses to treatment at an unifiable …
View article: Bevacizumab mitigates codon-specific effects of trifluridine/tipiracil on efficacy outcome parameters in metastatic colorectal cancer
Bevacizumab mitigates codon-specific effects of trifluridine/tipiracil on efficacy outcome parameters in metastatic colorectal cancer Open
This real-world study indicates that the efficacy of FTD/TPI + bevacizumab is independent of RAS mutational status and that bevacizumab may therefore mitigate the potentially limited efficacy of FTD/TPI monotherapy in the KRAS G12-mutated …
View article: The Global ALPL gene variant classification project: Dedicated to deciphering variants
The Global ALPL gene variant classification project: Dedicated to deciphering variants Open
View article: Real world evidence reveals improved survival outcomes in biliary tract cancer through molecular matched targeted treatment
Real world evidence reveals improved survival outcomes in biliary tract cancer through molecular matched targeted treatment Open
View article: CAR virus receptor mediates erythroid differentiation and migration and is downregulated in MDS
CAR virus receptor mediates erythroid differentiation and migration and is downregulated in MDS Open
View article: PB2186: MOLECULAR RESPONSE TO INTERFERON IN PREFIBROTIC PRIMARY MYELOFIBROSIS- RETROSPECTIVE SINGLE CENTER STUDY
PB2186: MOLECULAR RESPONSE TO INTERFERON IN PREFIBROTIC PRIMARY MYELOFIBROSIS- RETROSPECTIVE SINGLE CENTER STUDY Open
Topic: 16. Myeloproliferative neoplasms - Clinical Background: Interferon is a well-known therapy for a long time in early stage myeloproliferative neoplasms; its good efficacy and potential disease modifying effect is very much appreciate…
View article: Overall survival benefit of patients with biliary tract cancer receiving molecular profiling: a real-world multicenter retrospective cohort analysis
Overall survival benefit of patients with biliary tract cancer receiving molecular profiling: a real-world multicenter retrospective cohort analysis Open
Biliary tract cancers are rare cancers with poor prognosis due to a lack of therapeutic options, especially after the failure of first-line systemic treatment. Targeted treatments for this clinical situation are promising and have entered …
View article: <i>TERT</i> Promoter Mutation c.-124C&gt;T Commonly Occurs in Low-Grade Fibromatosis-like Metaplastic Breast Carcinoma
<i>TERT</i> Promoter Mutation c.-124C>T Commonly Occurs in Low-Grade Fibromatosis-like Metaplastic Breast Carcinoma Open
Context.— Low-grade fibromatosis-like metaplastic carcinoma (FLMC) is a very rare subtype of triple-negative metaplastic (spindle cell) breast carcinoma. It is characterized by the proliferation of spindle cells closely resembling fibromat…
View article: Response prediction by mutation- or methylation-specific detection of ctDNA dynamics in pretreated metastatic colorectal cancer
Response prediction by mutation- or methylation-specific detection of ctDNA dynamics in pretreated metastatic colorectal cancer Open
Background: Serial analysis of circulating tumor DNA (ctDNA) levels is a promising tool for both relapse prediction in the curative setting, as well as predicting clinical benefit from systemic treatment in metastasic colorectal cancer (mC…
View article: Prediction of response to systemic treatment by kinetics of circulating tumor DNA in metastatic pancreatic cancer
Prediction of response to systemic treatment by kinetics of circulating tumor DNA in metastatic pancreatic cancer Open
Introduction Pretherapeutic detectable circulating tumor DNA (ctDNA) represents a promising prognostic biomarker for predicting relapse and overall survival in patients with metastatic pancreatic cancer. However, the prognostic value of ct…
View article: Spontaneous reshaping of vertebral fractures in an adolescent with osteogenesis imperfecta
Spontaneous reshaping of vertebral fractures in an adolescent with osteogenesis imperfecta Open
Vertebral reshaping is explained by the stabilization of bone mineral density (BMD) and the remaining growth capacity the children. We hypothesize that spontaneous reshaping may occur in milder forms of OI, and that puberty may be a key me…
View article: Data of ‘Circulating tumor DNA correlates with tumor burden and predicts outcome in pancreatic cancer irrespective of tumor stage’
Data of ‘Circulating tumor DNA correlates with tumor burden and predicts outcome in pancreatic cancer irrespective of tumor stage’ Open
View article: Impact of age on the cumulative risk of transformation in patients with chronic myelomonocytic leukaemia
Impact of age on the cumulative risk of transformation in patients with chronic myelomonocytic leukaemia Open
In older patients with chronic myelomonocytic leukaemia (CMML) and limited life expectancy due to age and or comorbidities, it is particularly important to consider the risk of transformation for individualised treatment decisions. There i…
View article: Successful kidney transplantation in a patient with pre-existing chronic myeloid leukemia treated with imatinib
Successful kidney transplantation in a patient with pre-existing chronic myeloid leukemia treated with imatinib Open
Active malignancy is an absolute contraindication to kidney transplantation. As for chronic myeloid leukemia (CML), a Philadelphia chromosome-positive myeloproliferative neoplasm, the introduction of tyrosine kinase inhibitors has transfor…
View article: The Austrian biodatabase for chronic myelomonocytic leukemia (ABCMML)
The Austrian biodatabase for chronic myelomonocytic leukemia (ABCMML) Open
In the Austrian biodatabase for chronic myelomonocytic leukemia (ABCMML) clinicolaboratory real-life data have been captured from 606 CMML patients from 14 different hospitals over the last 30 years. It is the only large biodatabase worldw…
View article: P02.10 Aggressiveness of meningiomas is predicted by cell immortalization in vitro and dependent on TERT promoter mutations
P02.10 Aggressiveness of meningiomas is predicted by cell immortalization in vitro and dependent on TERT promoter mutations Open
TERT promoter mutations in meningiomas were recently found to be strongly prognostic and associated with malignant progression and risk of recurrence. However, the cellular factors underlying meningioma aggressiveness are comparably unexpl…
View article: <i>TERT</i>promoter mutations are associated with poor prognosis and cell immortalization in meningioma
<i>TERT</i>promoter mutations are associated with poor prognosis and cell immortalization in meningioma Open
TERT promoter mutations drive meningioma aggressiveness, resulting in reduced patient survival, but might also open novel therapeutic options for progressive disease.
View article: Aktuelle Nachrichten
Aktuelle Nachrichten Open
View article: Laboratory diagnostics in hematology—a new “Educational” series
Laboratory diagnostics in hematology—a new “Educational” series Open